Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Meta Platforms Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Meta Platforms Inc trades at $663.56 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 209× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Meta Platforms Inc pays a 0.32% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | META | |
|---|---|---|
Market Cap | $8.04B | $1.68T |
Sector | Health | Media |
52-Week High | $339.75 | $790.00 |
52-Week Low | $241.71 | $525.72 |
Enterprise Value | $7.85B | $1.68T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Meta Platforms (META) trades at $656.73, down 1.86% on the day, amid strong technical and fundamental momentum. The stock maintains a bullish technical signal with key support at $653 and resistance at $663. Recent earnings beats, including Q1 2026 EPS of $10.44 versus $6.70 expected, highlight robust profitability with a 32.84% net margin. The launch of Muse Spark AI and a $21 billion deal with CoreWeave underscore strategic growth initiatives, though legal challenges persist.
Outlook remains positive with a consensus price target of $815.44, implying 24% upside. Strengths include dominant market position, AI innovation, and strong cash flow. Risks involve regulatory lawsuits, high capital expenditure, and competitive pressures. Institutional sentiment is bullish with 79% buy ratings, but investors should monitor litigation outcomes and AI monetization progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
